Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human TNFSF11 Antikörper:
anti-Mouse (Murine) TNFSF11 Antikörper:
anti-Rat (Rattus) TNFSF11 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal TNFSF11 Primary Antibody für ChIP, FACS - ABIN252476
Kikuchi, Matsuguchi, Tsuboi, Mitani, Tanaka, Matsuoka, Yamamoto, Hishikawa, Noguchi, Yoshikai: Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. in Journal of immunology (Baltimore, Md. : 1950) 2001
Show all 20 Pubmed References
Human Polyclonal TNFSF11 Primary Antibody für IF (p), IHC (p) - ABIN672696
Yang, Li, Yang, Shen, Zou, Zhu, Zhang, Yang, Li: Efficacy and safety of echinacoside in a rat osteopenia model. in Evidence-based complementary and alternative medicine : eCAM 2013
Show all 15 Pubmed References
Human Polyclonal TNFSF11 Primary Antibody für IF (p), IHC (p) - ABIN668556
Zhang, Liu, Li, Bai: Mycobacterium tuberculosis 10-kDa co-chaperonin regulates the expression levels of receptor activator of nuclear factor-?B ligand and osteoprotegerin in human osteoblasts. in Experimental and therapeutic medicine 2015
Show all 11 Pubmed References
Human Monoclonal TNFSF11 Primary Antibody für ChIP, CyTOF - ABIN252546
Hsu, Lacey, Dunstan, Solovyev, Colombero, Timms, Tan, Elliott, Kelley, Sarosi, Wang, Xia, Elliott, Chiu, Black, Scully, Capparelli, Morony, Shimamoto, Bass, Boyle: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. in Proceedings of the National Academy of Sciences of the United States of America 1999
Show all 10 Pubmed References
Human Monoclonal TNFSF11 Primary Antibody für ELISA - ABIN4249074
Pearse, Sordillo, Yaccoby, Wong, Liau, Colman, Michaeli, Epstein, Choi: Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. in Proceedings of the National Academy of Sciences of the United States of America 2001
Show all 9 Pubmed References
Human Monoclonal TNFSF11 Primary Antibody für FACS, IHC (fro) - ABIN252684
Yoneda, Ishimaru, Arakaki, Kobayashi, Izawa, Moriyama, Hayashi: Estrogen deficiency accelerates murine autoimmune arthritis associated with receptor activator of nuclear factor-kappa B ligand-mediated osteoclastogenesis. in Endocrinology 2004
Show all 3 Pubmed References
Human Monoclonal TNFSF11 Primary Antibody für CyTOF, FACS - ABIN4361916
Shetty, Pepin, Charest, Perron, Doyle, Voisine, Dagenais, Pibarot, Mathieu: Expression of bone-regulatory proteins in human valve allografts. in Heart (British Cardiac Society) 2006
Show all 3 Pubmed References
Mouse (Murine) Monoclonal TNFSF11 Primary Antibody für IHC (fro), FACS - ABIN2479510
Andersen, Jørgensen, Bardram, Hilsted: Screening for multiple endocrine neoplasia type 1 in patients with recognized pituitary adenoma. in Clinical endocrinology 1991
Show all 4 Pubmed References
Data report that in postmenopausal women without known genetic predisposition, high RANKL serum levels stratify a subpopulation of women at high risk of developing breast cancer 12-24 months before diagnosis.
Data suggest that STAT6 (zeige STAT6 Antikörper) and RANKL are involved in regulation of apoptosis, gene expression, and cell proliferation in hepatocellular carcinoma cell lines; depletion of STAT6 (zeige STAT6 Antikörper) using RNA interference increases apoptosis; this mechanism involves down-regulation of expression of RANKL. (STAT6 (zeige STAT6 Antikörper) = signal transducer and activator of transcription 6 (zeige STAT6 Antikörper); RANKL = receptor activator of nuclear factor kappa B ligand)
Positivity of RANKL and anti-CCP2 (zeige AGBL2 Antikörper) yielded significant risk for progression with negativity for both as reference. No single nucleotide polymorphism encoding TNFSF11 or SOST (zeige SOST Antikörper) was associated with increased concentrations of the factors.
The compound with greatest potential is E05657 with high activity and low effective concentration in the HTS (zeige APCDD1 Antikörper) system. It increases the OPG/RANKL ratio and OPG (zeige TNFRSF11B Antikörper) secretion, decreases the NFATc1 (zeige NFATC1 Antikörper) expression, and reduces osteoclastogenesis in vitro
Our study suggests that the RANKL/RANK pathway contributes to the development and maintenance of the immunosuppressive tumor microenvironment and denosumab may be a promising adjuvant therapy targeting TAMs in cancer of apocrine origin
RANKL/Osteoprotegerin (zeige TNFRSF11B Antikörper) have roles in bone turnover in Hashimoto Thyroiditis
present clear evidence that TRAIL can block several key signalling actions of RANKL in vascular cells, providing further evidence of its vasoprotective potential
main finding is that OPG (zeige TNFRSF11B Antikörper) levels decreased significantly during 8 weeks of alcohol abstinence.
Studies showed that the central hypothalamic-pituitary regulatory system, via it's relative hormones, seems to control OPG/RANKL/RANK system function, and the pulsatility and circadian rhythmicity of these hormones may induce an oscillatory fluctuation of the OPG/ RANKL ratio. Also, psycological characteristics may provoke a shift of the OPG/ RANKL ratio towards an unbalanced or a balanced status. [review]
Studies strongly implicates RANK and RANKL as key molecules involved in the initiation of BRCA1-associated breast cancer. [review]
RANKL/RANK control progenitor cell expansion and tumorigenesis in inherited breast cancer.
Rankl(-/-) bone marrow-mesenchymal stromal cell displayed reduced clonogenicity and osteogenic capacity.
In this study, the authors identified by gene expression profiling that microgravity induces high levels of TRAIL expression in murine preosteoclast cells in the absence of RANKL stimulation compared to ground based cultures.
These results suggest that LOX (zeige LOX Antikörper) has the ability to induce RANKL expression on stromal cells; however, it fails to substitute for RANKL in osteoclastogenesis.
Results demonstrated picroside II strongly inhibited RANKL-induced osteoclast formation when added during the early stage of BMMs cultures, suggesting that it acts on osteoclast precursors to inhibit RANKL/RANK signaling.
loss of BMP signaling specifically in osteocytes dramatically increases bone mass presumably through simultaneous inhibition of RANKL and SOST (zeige SOST Antikörper), leading to osteoclast inhibition and Wnt (zeige WNT2 Antikörper) activation together.
The potentiation of RANKL induced CTX release by dexamethasone was significantly less in bone marrow macrophage cells from mice with conditional knockout of the osteoclastic glucocorticoid receptor (zeige NR3C1 Antikörper) and completely absent in cells from GR(dim) mice, which carry a point mutation in one dimerizing interface of the GC receptor.
findings demonstrate that mTORC1 activation-stimulated RANKL expression in B cells is sufficient to induce bone loss and osteoporosis. The study also established a link between mTORC1 and the RANKL/OPG axis via negative regulation of beta-catenin (zeige CTNNB1 Antikörper).
dihydroartemisinin inhibited RANKL-induced NF-kappaB (zeige NFKB1 Antikörper) and NFAT (zeige NFATC1 Antikörper) activity.
Cyanidin chloride is capable of inhibiting osteoclast formation, hydroxyapatite resorption and RANKL-induced signal pathways in vitro and ovariectomy-induced bone loss in vivo.
This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found.
TNF-related activation-induced cytokine
, osteoclast differentiation factor
, osteoprotegerin ligand
, receptor activator of nuclear factor kappa B ligand
, receptor activator of nuclear factor kappa-B ligand
, tumor necrosis factor ligand superfamily member 11
, tumor necrosis factor (ligand) superfamily, member 11
, Receptor activator of nuclear factor kappa-B ligand
, osteoclastogenesis inhibitory factor
, tumor necrosis factor receptor superfamily member 11B
, OPG ligand
, receptor activator of NF-kappaB ligand
, tumor necrosis factor-related activation-induced cytokine
, TNF superfamily member 11 L homeolog
, tumor necrosis factor superfamily member 11 L homeolog